Monopar Therapeutics Inc. $MNPR Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its position in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 9.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 158,437 shares of the company’s stock after selling 15,905 shares during the quarter. Wellington Management Group LLP’s holdings in Monopar Therapeutics were worth $14,670,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new position in Monopar Therapeutics in the 1st quarter worth approximately $673,000. Jane Street Group LLC acquired a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $377,000. Geode Capital Management LLC lifted its stake in Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after acquiring an additional 48,379 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares during the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Monopar Therapeutics in the 2nd quarter valued at $209,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Insider Transactions at Monopar Therapeutics

In related news, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the transaction, the director owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. This represents a 11.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 4,090 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total value of $455,585.10. Following the transaction, the director owned 7,396 shares in the company, valued at $823,840.44. This represents a 35.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MNPR shares. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Morgan Stanley reaffirmed an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a research report on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, Barclays reissued an “overweight” rating and issued a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $118.67.

Monopar Therapeutics Price Performance

MNPR opened at $117.56 on Tuesday. The firm has a fifty day moving average price of $110.24 and a 200 day moving average price of $77.64. Monopar Therapeutics Inc. has a 1 year low of $38.66 and a 1 year high of $124.82. The stock has a market cap of $788.83 million, a P/E ratio of -54.17 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. Equities analysts expect that Monopar Therapeutics Inc. will post -2.94 EPS for the current year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.